Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
34results about "CD45" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Kappa/lambda chimeric antigen receptors
InactiveUS20170049819A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigenAntigen receptors
The invention provides improved vector composition comprising chimeric antigen receptor for adoptive T cell therapies.
Owner:BLUEBIRD BIO INC
CD45 disrupted nucleic acid
A mammal lacking expression of particular CD45 isoform in certain cells of the immune system is provided. The mammal may optionally contain a transgene encoding the CD45RO isoform. Also provided are methods of using these mammals.
Owner:AMGEN INC +1
Cell
InactiveUS20160296562A1Avoid problemsGood treatment effectPeptide/protein ingredientsHydrolasesAntigen bindingBinding domain
The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising : (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, and wherein each of the first and second CARs is an activating CAR comprising an activating endodomain.
Owner:AUTOLUS LIMIED
Cell
ActiveUS20160289293A1Good choiceLow toxicityPeptide/protein ingredientsHydrolasesAntigen receptorAntigen binding
The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, and wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain.
Owner:AUTOLUS LIMIED
Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and usage method thereof
Owner:ICELL GENE THERAPEUTICS LLC
Cell
ActiveUS20160289294A1Maximally potent activityHigh activityHydrolasesPeptide/protein ingredientsAntigen receptorAntigen binding
The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, wherein the spacer of the first CAR is different to the spacer of the second CAR and wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain.
Owner:AUTOLUS LIMIED
Immunologically discernible cell surface variants for use in cell therapy
PendingCN110191948ALow antigenicityHydrolasesStable introduction of DNAAntigen receptorsCell therapy
The invention relates to a mammalian cell, particularly a human cell, expressing a first isoform of a surface protein, wherein the first isoform is functionally indistinguishable, but immunologicallydistinguishable from a second isoform, for use in a medical treatment of a patient having cells expressing the second isoform form of the surface protein. The invention further relates to an agent selected from 1) a compound comprising, or consisting of, an antibody or antibody-like molecule and 2) an immune effector cell bearing an antibody-like molecule or an immune effector cell bearing a chimeric antigen receptor, for use in a method of treatment of a medical condition, wherein the agent is specifically reactive to either a first or a second isoform of a surface protein, wherein the firstisoform is functionally indistinguishable, but immunologically distinguishable from the second isoform, and wherein the agent is administered to ablate a cell bearing the isoform that the agent is reactive to.
Owner:UNIVERSITY OF BASEL
A cell comprising a chimeric antigen receptor (CAR)
InactiveUS20200188434A1Polypeptide with localisation/targeting motifOrganic active ingredientsIntracellular signallingAntigen receptor
The present invention provides a cell which comprises; (i) a chimeric antigen receptor (CAR) which comprises an antigen binding domain and an intracellular signalling domain; (ii) a membrane tethering component (MTC) which comprises a first dimerization domain; and (Hi) a signal-dampening component (SDC) comprising a signal-dampening domain (SDD) and a second dimerization domain which specifically binds the first dimerisation domain of the membrane-tethering component. Dimerisation between the MTC and SDC may be controllable with an agent, meaning that the agent can be used to control CAR-mediated cell signalling.
Owner:AUTOLUS LIMIED
Slit2D2-chimeric antigen receptor and application thereof
ActiveCN107298715AKilling specificitySpecific recognition abilityPeptide/protein ingredientsAntibody mimetics/scaffoldsSlit2 proteinAntigen
The invention provides a chimeric antigen receptor (CAR) and a CAR encoding gene. The CAR comprises an extracellular structural domain capable of binding antigens, a transmembrane structural domain and intracellular immune costimulatory molecules, wherein the extracellular structural domain comprises a D2 structural domain of a Slit2 protein. In addition the invention also provides a chimeric antigen receptor expression cell, and the CAR encoding gene is introduced into the cell, so that the CAR is expressed on the surface of the cell. The CAR or the CAR expression cell provided by the invention can be used as cell medicines in the treatment of tumor diseases. The CAR provided by the invention can be used to modify cells, especially T cells, and modified T cells can specifically recognize and kill or wound tumors and have more efficient tumor killing activity.
Owner:ASCLEPIUS SUZHOU TECH CO GRP CO LTD
Compound Chimeric Antigen Receptor (CCAR) Targeting Multiple Antigents, Compositions and Methods of Use Thereof
PendingUS20200308541A1Improve securityKilling cellAntibody mimetics/scaffoldsTransferasesAntigen receptorBiochemistry
In one embodiment, the present disclosure provides an engineered cell having a first chimeric antigen receptor polypeptide including a first antigen recognition domain, a first signal peptide, a first hinge region, a first transmembrane domain, a first costimulatory domain, and a first signaling domain; and a second chimeric antigen receptor polypeptide including a second antigen recognition domain, a second signal peptide, a second hinge region, a second transmembrane domain, a second co-stimulatory domain, and a second signaling domain; wherein the first antigen recognition domain is different than the second antigen recognition domain.
Owner:ICELL GENE THERAPEUTICS LLC
Compositions and methods for inhibiting shiga toxin and shiga-like toxin
The present invention provides compositions and methods for treating or preventing infection by shiga toxin producing bacteria.
Owner:RECOPHARMA AB
Anti-L1CAM antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same
PendingCN112912401AImprove featuresHigh affinityAntipyreticAnalgesicsAntiendomysial antibodiesAntigen Binding Fragment
The present invention relates to an anti-L1CAM antibody specifically binding to L1CAM antigen or an antigen-binding fragment thereof, a chimeric antigen receptor comprising the same, and uses thereof. The anti-L1CAM antibody or the antigen-binding fragment of the present invention is excellent in specificity and affinity to L1CAM and thus may be used in the treatment and diagnosis of cancers related to high expression of L1CAM and diseases related to inflammatory disorders. In particular, when the chimeric antigen receptor comprising the anti-L1CAM antibody of the present invention is expressed in effector cells such as T lymphocytes, the chimeric antigen receptor may be effectively used as immunotherapy for cancers related to L1CAM and inflammatory disorders.
Owner:CARTEXELL INC
Compositions and methods for treating cancer with Anti-ror1 immunotherapy
Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions,relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Owner:LENTIGEN TECH INC
Methods and Compositions for Promoting Immune Cell Function
ActiveUS20200131239A1Function increaseProvide benefitsPeptide/protein ingredientsAntibody mimetics/scaffoldsNanoparticleImmune Cell Function
The present disclosure features, at least in part, methods for conserving cell function, e.g., immune cell function, e.g., after one or more cycles of freezing and / or thawing the nucleated cell. In embodiments, the methods comprise contacting an immune cell with a protein nanoparticle comprising an IL-15 complex.
Owner:TORQUE THERAPEUTICS INC
Preparation method and application of enhanced Slit2 CAR-T and CAR-NK cells
ActiveCN107868791AEnhance immune killing activityHigh affinityGenetic material ingredientsMammal material medical ingredientsAbnormal tissue growthDisease
The invention provides a preparation method and application of enhanced Slit2 CAR-T and CAR-NK cells. The enhanced CAR-T cell comprises a T cell of an enhanced CAR embedded antigen receptor, and the enhanced CAR-NK cell comprises a NK cell of an enhanced CAR embedded antigen receptor, wherein the enhanced CAR embedded antigen receptor includes an extracellular structural domain capable of combining with an antigen, a transmembrane structural domain, intracellular immune costimulatory molecules, an entry site IRES of internal ribosome, and HAC-HSA that are connected in sequence, wherein the extracellular structural domain includes a D2 structural domain of Slit2 protein. The enhanced CAR-T cell and CAR-NK cells can close PDL-1 inhibitory signals, improves the killing activity of CAR-immunocyte, and activates tumor-infiltrating immunocyte. The enhanced CAR-immunocyte can be taken as a cell medicine for treating tumor diseases. The transformed immunocyte can specifically recognize and kill tumor and has efficient tumor-killing activity.
Owner:ASCLEPIUS SUZHOU TECH CO GRP CO LTD
Methods and compositions for promoting immune cell function
InactiveCN109715196APeptide/protein ingredientsAntibody mimetics/scaffoldsNanoparticleImmune Cell Function
Owner:TORQUE THERAPEUTICS INC
Transgenic mice comprising CD45 knockout
A mammal lacking expression of particular CD45 isoform in certain cells of the immune system is provided. The mammal may optionally contain a transgene encoding the CD45RO isoform. Also provided are methods of using these mammals.
Owner:ONTARIO CANCER INST
Compositions and methods for TCR reprogramming using fusion proteins
Provided herein are recombinant nucleic acids encoding a T cell receptor (TCR) fusion protein (TFP), modified human immune cells expressing the encoded molecules, and methods of their use in the treatment of diseases, including cancer.
Owner:TCR2 THERAPEUTICS INC
System and method for the treatment of disease using a hyperspecific modified protein system
PendingUS20190192678A1Minimal and no side effectOvercome disadvantagesPolypeptide with localisation/targeting motifImmunoglobulin superfamilyDiseaseSide effect
A hyperspecific MP system is a system of at least 3 different types of Modified Proteins expressed on / in any cell type and operating together in a treatment, diagnostic, commercial method, or other commercial method(s). Using multiple Modified Proteins can significantly increase the specificity of cancer treatment among many others and decrease side effects of treatments.
Owner:NOVATHER INC
Nucleic acid construct
ActiveUS20180099994A1Inhibit expressionLimited amountPolypeptide with localisation/targeting motifImmunoglobulin superfamilyNucleic acid sequencingAmino acid
The present invention provides a nucleic acid construct comprising the following structure: A-X—B in which A is nucleic acid sequence encoding a first polypeptide which comprises a first signal peptide; B is nucleic acid sequence encoding a second polypeptide which comprises a second signal peptide and X is a nucleic acid sequence which encodes a cleavage site, wherein the first signal peptide or the second signal peptide comprises one or more mutation(s) such that it has fewer hydrophobic amino acids.
Owner:AUTOLUS LIMIED
Ligands and libraries of ligands
The invention relates to variants of Target Biological Molecules (TBMs), such as proteins, peptides and other amino acid sequences that are modified to include cysteine residues at predetermined positions within the TBM. The position of amino acid residues within the TBM that are modified to be cysteine residues is selected for its proximity to ligand binding sites within the TBM. Once an amino acid residue, or the DNA encoding the residue, is modified to cysteine, the TBM linked to potential binding ligands by forming a covalent bond through the cysteine thiol (—SH) reactive group of the variant.
Owner:WELLS JIM +2
Cell comprising chimeric antigen receptor (CAR)
PendingCN110621694APolypeptide with localisation/targeting motifOrganic active ingredientsIntracellular signallingAntigen receptor
The present invention provides a cell which comprises; (i) a chimeric antigen receptor (CAR) which comprises an antigen binding domain and an intracellular signalling domain; (ii) a membrane tetheringcomponent (MTC) which comprises a first dimerization domain; and (Hi) a signal-dampening component (SDC) comprising a signal-dampening domain (SDD) and a second dimerization domain which specificallybinds the first dimerisation domain of the membrane-tethering component. Dimerisation between the MTC and SDC may be controllable with an agent, meaning that the agent can be used to control CAR-mediated cell signalling.
Owner:AUTOLUS LIMIED
Preparation method of T cell with cell surface markers of CD45RA < + > and CCR7 < + >
PendingCN114599784AEasy to operatePolypeptide with localisation/targeting motifGenetically modified cellsSurface markerMedicine
The present invention addresses the problem of providing a technique for eliminating the depletion of T cells, which is a problem in T cell transfer therapy and the like, and improving the activity of T cells. T cells having cell surface markers of CD45RA + and CCR7 + can be prepared by culturing activated T cells in the presence of (a) a cell culture supernatant of stromal cells or (b) CXCL12.
Owner:DAIICHI SANKYO CO LTD +1
Recombinant vector for expressing target protein in plant cell
ActiveUS20200354737A1Improve expression levelEasy to usePolypeptide with localisation/targeting motifPeptide/protein ingredientsProtein targetPlant cell
Provided is a technique for highly expressing a target protein in a plant cell by using a glycosylation domain, a recombinant vector comprising a gene encoding a fusion protein of a glycosylation domain and a target protein, a recombinant cell, a transformed plant, and a method of producing a target protein using these.
Owner:BIOAPPL
Anti-l1cam antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same
PendingUS20220242948A1High affinityStrong specificityAntipyreticAnalgesicsAntigen receptorAntiendomysial antibodies
The present invention relates to an anti-L1CAM antibody specifically binding to L1CAM antigen or an antigen-binding fragment thereof, a chimeric antigen receptor comprising same, and uses thereof. The anti-L1CAM antibody or the antigen-binding fragment of the present invention is excellent in specificity and affinity to L1CAM and thus may be used in the treatment and diagnosis of cancers related to high expression of L1CAM and diseases related to inflammatory disorders. In particular, when the chimeric antigen receptor comprising the anti-L1CAM antibody of the present invention is expressed in effector cells such as T lymphocytes, the chimeric antigen receptor may be effectively used as immunotherapy for cancers related to L1CAM and inflammatory disorders.
Owner:CARTEXELL INC
Chimeric antigen receptor tumor infiltrating lymphocytes
Disclosed are compositions and methods for targeted treatment of infections and cancers expressing cancers. In particular, tumor infiltrating lymphocytes (TILs) are genetically engineered to express chimeric antigen receptor (CAR) polypeptides to produce CAR-TILs that can be used with adoptive cell transfer to target, penetrate, and kill solid tumor masses. Therefore, also disclosed are methods of providing an immunotherapy in a subject with an infection or cancer that involves adoptive transfer of the disclosed CAR-TILs.
Owner:H 李 莫菲特癌症中心和研究所公司
Nucleic acid construct
The present invention provides a nucleic acid construct comprising the following structure: A-X-B in which A is nucleic acid sequence encoding a first polypeptide which comprises a first signal peptide; B is nucleic acid sequence encoding a second polypeptide which comprises a second signal peptide and X is a nucleic acid sequence which encodes a cleavage site, wherein the first signal peptide orthe second signal peptide comprises one or more mutation(s) such that it has fewer hydrophobic amino acids.
Owner:AUTOLUS LIMIED
Slit2d2-chimeric antigen receptor and application thereof
ActiveUS20190231819A1High tumoricidal activityHigh transfection efficiencyPeptide/protein ingredientsAntibody mimetics/scaffoldsAntigenSlit2 protein
A chimeric antigen receptor (CAR) and a gene encoding the CAR. The CAR comprises an extracellular domain capable of binding to an antigen, a transmembrane domain, and intracellular immune co-stimulatory molecule, wherein the extracellular domain comprises a D2 domain of a Slit2 protein. A chimeric antibody-expressing cell, which introduces a gene encoding the CAR into a cell so as to express the CAR on the surface of the cell. The CAR or CAR-expressing cell can be used as a cell drug for the treatment of tumor diseases. By using the CAR for engineering cells, especially T cells, the engineered T cells can specifically recognize and kill tumors, and have higher tumoricidal activity.
Owner:ASCLEPIUS SUZHOU TECH CO GRP CO LTD
Molecules and their derivatives directed aganist cd45
PendingUS20200338219A1Radioactive preparation carriersMammal material medical ingredientsDiseaseEpitope
The present disclosure provides epitopes of CD45, and binding agents such as antibodies, antibody fragments, peptides, and small molecules capable of binding to those epitopes. The present disclosure also provides methods of treating cancers, hematological diseases and disorders, and immune diseases and disorders, using these binding agents.
Owner:ACTINIUM PHARMA
Preparation method and application of enhanced slit2 CAR-T and CAR-NK cells
ActiveCN107868791BEnhance immune killing activityHigh affinityGenetic material ingredientsMammal material medical ingredientsSlit2 proteinAntigen
The present invention provides a preparation method and application of enhanced Slit2CAR-T and CAT-NK cells, the enhanced CAR-T and CAT-NK cells are respectively T cells and NK cells containing enhanced CAR chimeric antigen receptors , wherein the enhanced CAR chimeric antigen receptor includes an extracellular domain capable of binding antigen, a transmembrane domain, an intracellular immune costimulatory molecule, an internal ribosome entry site IRES and HAC-HSA in series; wherein the extracellular domain Includes the D2 domain of the Slit2 protein. The enhanced CAR-T cells and enhanced CAR-NK cells of the present invention can block the PDL-1 inhibitory signal, enhance the killing activity of CAR-immune cells, and activate tumor-infiltrating immune cells; the enhanced CAR-immune cells can be used as Cellular medicine is used in the treatment of tumor diseases, so that the modified immune cells can specifically recognize and kill tumors, and have more efficient tumor killing activity.
Owner:ASCLEPIUS SUZHOU TECH CO GRP CO LTD
Popular searches
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com